Title Issue Date
Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial Hinojosa, J.; Gomollon, F.; Garcia, S.; Bastida, G.; Cabriada, JL, et al Issued date: 2007 DOI: 10.1111/j.1365-2036.2006.03232.x Source: Aliment Pharmacol Therapeutics, [ISSN 0269-2813], v. 25 (4), p. 409–418, (2007). JCR: 3,201 - Q2 SCIE
Long‐term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study Chaparro, María; Hermida, Sandra; Acosta, Diana; Fernández Clotet, Agnès; Arroyo, Maite, et al Issued date: 2024 DOI: 10.1111/apt.18230 Source: Alimentary Pharmacology and Therapeutics [ISSN 0269-2813], p. 1-14, (Sep 2024). SJR: 2,794 - Q1 JCR: 6,6 - Q1 SCIE MIAR ICDS: 11,0
Long‐Term Outcomes Following Withdrawal of Anti‐Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long‐Term Study of GETECCU Casanova, María José; Rubín de Célix, Cristina; Riestra, Sabino; Lucendo, Alfredo J.; Guzman Benitez,Jose Manuel , et al Issued date: 2025 DOI: 10.1111/apt.70172 Source: Alimentary Pharmacology and Therapeutics [ISSN 0269-2813], (2025). SJR: 2,794 - Q1 JCR: 6,6 - Q1 SCIE MIAR ICDS: 11,0